PanktiReidPankti Reid41.7886000000000087.598699999999993818Reid, PanktiAssistant Professorprns:coAuthorOfcoauthor ofprns:emailEncryptedemail addressFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD001172Disorders791630.874319Arthritis, RheumatoidD001327Disorders1332410.830421Autoimmune DiseasesD001168Disorders35460.962256ArthritisRadiation and Cellular OncologyMedicine-General Internal MedicineMedicine-Rheumatology29759118Ventura I, Reid P, Jan RPrimary careApproach to Patients with Suspected Rheumatic Disease. Prim Care. 2018 Jun; 45(2):169-180.Prim Care2018-06-01T00:00:002018Approach to Patients with Suspected Rheumatic Disease.30614917Yuen C, Reid P, Zhang Z, Soliven B, Luke JJ, Rezania KJournal of immunotherapy (Hagerstown, Md. : 1997)Facial Palsy Induced by Checkpoint Blockade: A Single Center Retrospective Study. J Immunother. 2019 04; 42(3):94-96.J Immunother2019-04-01T00:00:002019Facial Palsy Induced by Checkpoint Blockade: A Single Center Retrospective Study.31204194Gallan AJ, Alexander E, Reid P, Kutuby F, Chang A, Henriksen KJAmerican journal of kidney diseases : the official journal of the National Kidney FoundationRenal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors. Am J Kidney Dis. 2019 12; 74(6):853-856.Am J Kidney Dis2019-06-14T00:00:002019Renal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors.Chicago60637ILIazsminVenturaIazsmin Ventura41.7886000000000087.598699999999993802Ventura, IazsminAssistant Professor2.012720.00304532128research areas1.028760.044221427coauthor of61.05287.3525860similar to1131selected publicationsAuthorship 1312434Authorship 1310772Authorship 131699310978288Vaskova M, Bentley AM, Marshall S, Reid P, Thummel CS, Andres AJGeneticsGenetic analysis of the Drosophila 63F early puff. Characterization of mutations in E63-1 and maggie, a putative Tom22. Genetics. 2000 Sep; 156(1):229-44.Genetics2000-09-01T00:00:002000Genetic analysis of the Drosophila 63F early puff. Characterization of mutations in E63-1 and maggie, a putative Tom22.Authorship 134737131832802Reid P, Miloslavsky EM, Dua AClinical rheumatologyTeacher training for rheumatology fellows: a national needs assessment of fellows and program directors. Clin Rheumatol. 2020 Mar; 39(3):673-680.Clin Rheumatol2019-12-12T00:00:002019Teacher training for rheumatology fellows: a national needs assessment of fellows and program directors.Authorship 1367422Authorship 137987232488861Strohbehn GW, Reid PD, Ratain MJClinical pharmacology and therapeuticsApplied Clinical Pharmacology in a Crisis: Interleukin-6 Axis Blockade and COVID-19. Clin Pharmacol Ther. 2020 09; 108(3):425-427.Clin Pharmacol Ther2020-07-04T00:00:002020Applied Clinical Pharmacology in a Crisis: Interleukin-6 Axis Blockade and COVID-19.Authorship 139035232641238Kurnit KC, Reid P, Moroney JW, Fleming GFGynecologic oncologyImmune checkpoint inhibitors in women with gynecologic cancers: Practical considerations. Gynecol Oncol. 2020 09; 158(3):531-537.Gynecol Oncol2020-07-05T00:00:002020Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations.Authorship 1397252332743594Strohbehn GW, Heiss BL, Rouhani SJ, Trujillo JA, Yu J, Kacew AJ, Higgs EF, Bloodworth JC, Cabanov A, Wright RC, Koziol A, Weiss A, Danahey K, Karrison TG, Edens CC, Ventura IB, Pettit NN, Patel B, Pisano J, Strek ME, Gajewski TF, Ratain MJ, Reid PDmedRxiv : the preprint server for health sciencesCOVIDOSE: Low-dose tocilizumab in the treatment of Covid-19. medRxiv. 2020 Jul 26.medRxiv2020-07-26T00:00:002020COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19.Authorship 1420722333210302Strohbehn GW, Heiss BL, Rouhani SJ, Trujillo JA, Yu J, Kacew AJ, Higgs EF, Bloodworth JC, Cabanov A, Wright RC, Koziol AK, Weiss A, Danahey K, Karrison TG, Edens CC, Bauer Ventura I, Pettit NN, Patel BK, Pisano J, Strek ME, Gajewski TF, Ratain MJ, Reid PDClinical pharmacology and therapeuticsCOVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther. 2021 03; 109(3):688-696.Clin Pharmacol Ther2020-12-10T00:00:002020COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.Authorship 143566133506753Reid P, Danahey K, Lopez Velazquez M, Ratain MJ, O'Donnell PHClinical and experimental rheumatologyImpact and applicability of pharmacogenomics in rheumatology: an integrated analysis. Clin Exp Rheumatol. 2021 Nov-Dec; 39(6):1385-1393.Clin Exp Rheumatol2021-01-15T00:00:002021Impact and applicability of pharmacogenomics in rheumatology: an integrated analysis.Medicine-Hematology and OncologyMedicine-Pulmonary and Critical CareAuthorship 143958133528524Reid PD, Cifu AS, Bass ARJAMAManagement of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy. JAMA. 2021 Feb 02; 325(5):482-483.JAMA2021-02-02T00:00:002021Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy.Authorship 144978833736690Hines J, Daily E, Pham AK, Shea CR, Nadeem U, Husain AN, Stadler WM, Reid PJournal of medical case reportsSteroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report. J Med Case Rep. 2021 Mar 19; 15(1):124.J Med Case Rep2021-03-19T00:00:002021Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.Marina ChiaraGarassinoMarina Chiara Garassino41.7886000000000087.598699999999994025Garassino, Marina ChiaraProfessorAuthorship 147264334139194Strohbehn GW, Parker WF, Reid PD, Gellad WFThe Lancet. Global healthSocially optimal pandemic drug dosing. Lancet Glob Health. 2021 08; 9(8):e1049-e1050.Lancet Glob Health2021-06-14T00:00:002021Socially optimal pandemic drug dosing.Authorship 14755243Authorship 147740334228068Cifu AS, Bass AR, Reid PDJAMAImmune Checkpoint Inhibitor Therapy Toxicities-Reply. JAMA. 2021 07 06; 326(1):87-88.JAMA2021-07-06T00:00:002021Immune Checkpoint Inhibitor Therapy Toxicities-Reply.34228774WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Spiga F, Savovic J, Tierney J, Baron G, Benbenishty JS, Berry LR, Broman N, Cavalcanti AB, Colman R, De Buyser SL, Derde LPG, Domingo P, Omar SF, Fernandez-Cruz A, Feuth T, Garcia F, Garcia-Vicuna R, Gonzalez-Alvaro I, Gordon AC, Haynes R, Hermine O, Horby PW, Horick NK, Kumar K, Lambrecht BN, Landray MJ, Leal L, Lederer DJ, Lorenzi E, Mariette X, Merchante N, Misnan NA, Mohan SV, Nivens MC, Oksi J, Perez-Molina JA, Pizov R, Porcher R, Postma S, Rajasuriar R, Ramanan AV, Ravaud P, Reid PD, Rutgers A, Sancho-Lopez A, Seto TB, Sivapalasingam S, Soin AS, Staplin N, Stone JH, Strohbehn GW, Sunden-Cullberg J, Torre-Cisneros J, Tsai LW, van Hoogstraten H, van Meerten T, Veiga VC, Westerweel PE, Murthy S, Diaz JV, Marshall JC, Sterne JACJAMAAssociation Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA. 2021 08 10; 326(6):499-518.JAMA2021-08-10T00:00:002021Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.Authorship 148782334368414Wu M, Bennett JA, Reid P, Fleming GF, Kurnit KCGynecologic oncology reportsSuccessful treatment of squamous cell carcinoma arising from a presumed ovarian mature cystic teratoma with pembrolizumab. Gynecol Oncol Rep. 2021 Aug; 37:100837.Gynecol Oncol Rep2021-07-22T00:00:002021Successful treatment of squamous cell carcinoma arising from a presumed ovarian mature cystic teratoma with pembrolizumab.AndreaRamirez-GomezAndrea Ramirez-Gomez41.7886000000000087.598699999999994097Ramirez-Gomez, AndreaClinical AssociateAuthorship 149805134526389Reid P, Liew DF, Akruwala R, Bass AR, Chan KKJournal for immunotherapy of cancerActivated osteoarthritis following immune checkpoint inhibitor treatment: an observational study. J Immunother Cancer. 2021 09; 9(9).J Immunother Cancer2021-09-01T00:00:002021Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study.Authorship 151350134851244Reid P, Guler SAAnnals of the American Thoracic SocietyMortality Trends in Rheumatoid Arthritis: Zooming in on Interstitial Lung Disease. Ann Am Thorac Soc. 2021 12; 18(12):1953-1954.Ann Am Thorac Soc2021-12-01T00:00:002021Mortality Trends in Rheumatoid Arthritis: Zooming in on Interstitial Lung Disease.Authorship 155343335696731Saygin D, Ghosh N, Reid PJournal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseasesImmune Checkpoint Inhibitor-Associated Myositis: A Distinct Form of Inflammatory Myopathy. J Clin Rheumatol. 2022 Oct 01; 28(7):367-373.J Clin Rheumatol2022-06-14T00:00:002022Immune Checkpoint Inhibitor-Associated Myositis: A Distinct Form of Inflammatory Myopathy.D061067Chemicals & Drugs2139290.656166Antibodies, Monoclonal, HumanizedAuthorship 1589811Authorship 159498636595378Mathias K, Rouhani S, Olson D, Bass AR, Gajewski TF, Reid PThe oncologistAssociation Between Rheumatic Autoantibodies and Immune-Related Adverse Events. Oncologist. 2023 05 08; 28(5):440-448.Oncologist2023-05-08T00:00:002023Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.36539321Reid P, Cappelli LCBest practice & research. Clinical rheumatologyTreatment of rheumatic adverse events of cancer immunotherapy. Best Pract Res Clin Rheumatol. 2022 12; 36(4):101805.Best Pract Res Clin Rheumatol2022-12-18T00:00:002022Treatment of rheumatic adverse events of cancer immunotherapy.Authorship 161440136892846Reid P, Sparks JA, Bass ARJAMA oncologySteroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events. JAMA Oncol. 2023 05 01; 9(5):723-724.JAMA Oncol2023-05-01T00:00:002023Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events.D009369Disorders55628890.33847NeoplasmsAuthorship 1623744Authorship 162944337019614Bass AR, Abdel-Wahab N, Reid PD, Sparks JA, Calabrese C, Jannat-Khah DP, Ghosh N, Rajesh D, Aude CA, Gedmintas L, MacFarlane L, Arabelovic S, Falohun A, Mushtaq K, Haj FA, Diab A, Shah AA, Bingham CO, Chan KK, Cappelli LCAnnals of the rheumatic diseasesComparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis. 2023 07; 82(7):920-926.Ann Rheum Dis2023-04-05T00:00:002023Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis.37022615Wesevich A, He G, Tomczyk G, Reid PJournal of cancer education : the official journal of the American Association for Cancer EducationRole-Specific Curricular Needs for Identification and Management of Immune-Related Adverse Events. J Cancer Educ. 2023 10; 38(5):1486-1492.J Cancer Educ2023-04-06T00:00:002023Role-Specific Curricular Needs for Identification and Management of Immune-Related Adverse Events.Authorship 1635984Authorship 1640706Authorship 164197237259404Macklin M, Yadav S, Jan R, Reid PPharmaceuticals (Basel, Switzerland)Checkpoint Inhibitor-Associated Scleroderma and Scleroderma Mimics. Pharmaceuticals (Basel). 2023 Feb 08; 16(2).Pharmaceuticals (Basel)2023-02-08T00:00:002023Checkpoint Inhibitor-Associated Scleroderma and Scleroderma Mimics.37355249Ghosh N, Reid P, Aude CA, Kirschman J, Goodman S, Bykerk VP, Lakhanpal A, Rajesh D, Chan KK, Robinson WH, Bass ARRMD openAnticitrullinated peptide antibody epitope expansion and the HLA DRB1 'shared epitope' are less common in seropositive checkpoint inhibitor-induced inflammatory arthritis than in longstanding rheumatoid arthritis. RMD Open. 2023 06; 9(2).RMD Open2023-06-01T00:00:002023Anticitrullinated peptide antibody epitope expansion and the HLA DRB1 'shared epitope' are less common in seropositive checkpoint inhibitor-induced inflammatory arthritis than in longstanding rheumatoid arthritis.37385460Stahlbaum D, Jablonski R, Strek ME, Bestvina CM, Polley MY, Reid PRespiratory medicineAbnormalities on baseline chest imaging are risk factors for immune checkpoint inhibitor associated pneumonitis. Respir Med. 2023 Oct; 217:107330.Respir Med2023-06-28T00:00:002023Abnormalities on baseline chest imaging are risk factors for immune checkpoint inhibitor associated pneumonitis.Authorship 164537437490213Yang V, Kragstrup TW, McMaster C, Reid P, Singh N, Haysen SR, Robinson PC, Liew DFLDrug safetyManaging Cardiovascular and Cancer Risk Associated with JAK Inhibitors. Drug Saf. 2023 11; 46(11):1049-1071.Drug Saf2023-07-25T00:00:002023Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors.MedicinePathologyUniversity of ChicagoLinShenLin Shen41.7886000000000087.598699999999994427Shen, LinAssistant ProfessorAdamCifuAdam Cifu41.78927490000000-87.601250000000001241Cifu, AdamProfessor37596779Tokareva K, Reid P, Yang V, Liew D, Peterson AC, Baraff A, Giles J, Singh NExpert review of clinical immunologyJAK inhibitors and black box warnings: what is the future for JAK inhibitors? Expert Rev Clin Immunol. 2023 Jul-Dec; 19(11):1385-1397.Expert Rev Clin Immunol2023-09-04T00:00:002023JAK inhibitors and black box warnings: what is the future for JAK inhibitors?Authorship 1658262Mark J.RatainMark J. Ratain41.78927490000000-87.601250000000001401Ratain, Mark J.ProfessorMartinaDamoMartina Damo41.7886000000000087.598699999999994452Damo, MartinaAssistant ProfessorRaviSalgiaRavi Salgia41.78927490000000-87.601250000000001937Salgia, RaviEmeritus/Emerita, ProfessorRalph R.WeichselbaumxXB+DqgWEf/5hHlsaUXv9Gq0+s+oRalph R. Weichselbaum41.78927490000000-87.601250000000002521Weichselbaum, Ralph R.ProfessorMary ElizabethStrekMary Elizabeth Strek41.78927490000000-87.601250000000002563Strek, Mary ElizabethProfessorThomas F.GajewskiThomas F. Gajewski41.78927490000000-87.60125000000000355Gajewski, Thomas F.ProfessorPeter H.O'DonnellPeter H. O'Donnell41.78927490000000-87.60125000000000537O'Donnell, Peter H.Associate ProfessorAuthorship 168875138126033Reid P, Sandigursky S, Song J, Lopez-Olivo MA, Safa H, Cytryn S, Efuni E, Buni M, Pavlick A, Krogsgaard M, Abu-Shawer O, Altan M, Weber JS, Rahma OE, Suarez-Almazor ME, Diab A, Abdel-Wahab NOncoimmunologySafety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases. Oncoimmunology. 2023; 12(1):2261264.Oncoimmunology2023-10-30T00:00:002023Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases.Authorship 170141338399467Vitzthum von Eckstaedt H, Singh A, Reid P, Trotter KPharmaceuticals (Basel, Switzerland)Immune Checkpoint Inhibitors and Lupus Erythematosus. Pharmaceuticals (Basel). 2024 Feb 15; 17(2).Pharmaceuticals (Basel)2024-02-15T00:00:002024Immune Checkpoint Inhibitors and Lupus Erythematosus.CraigSmudaCraig Smuda41.7886000000000087.598699999999994521Smuda, CraigAssistant Professortrue1Emeritus/Emerita, ProfessorEmeritus/Emerita, Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1Clinical AssociateClinical Associatetrue1Assistant ProfessorAssistant Professortrue1Assistant ProfessorAssistant Professortrue1Assistant ProfessorAssistant Professortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessor1010